418 withdrawn. 418 Phase 2, 87 Phase 1, 38 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 418 | Withdrawn 418 |
| Phase 1 | 87 | Withdrawn 87 |
| Phase 3 | 38 | Withdrawn 38 |
Follow Nervous System Diseases: new trials by email Literature Review of Nervous System Diseases trials Research Report on Nervous System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ketamine and Midazolam Infusions for CRPS: Feasibility Study Ketamine, Midazolam, Normal Saline - Complex Regional Pain Syndromes | Phase 2 | Withdrawn | Stanford University | 2099-01-01 | 2024-11-22 | |
| Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease | Phase 2 | Withdrawn | Forest Hills Lab | 2027-11-01 | 2026-08-19 | |
| Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A scAAV1.tMCK.NTF3 - Charcot-Marie-Tooth Neuropathy Type 1A | Phase 1 / Phase 2 | Withdrawn | Nationwide Children's Hospital | 2027-04-01 | 2026-07-29 | |
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss Dexamethasone, Hyaluronic acid, Indocyanine green(ICG) - Hearing Loss, Sensorineural, Hearing Loss, Sudden | Phase 1 / Phase 2 | Withdrawn | Seoul National University Hospital | 2026-12-15 | 2026-05-22 | |
| A Study of ONC201 for Refractory Meningioma ONC201 - Meningioma, Refractory Meningioma | Phase 2 | Withdrawn | University of Nebraska | 2026-12-01 | 2026-01-26 | |
| Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis RNS60, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Withdrawn | Revalesio Corporation | 2026-10-01 | 2026-04-16 | |
| Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain Canadá, Canadá placebo, Dipyrone - Pain, Chronic | Phase 2 | Withdrawn | EMS | 2026-09-01 | 2023-09-08 | |
| Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy glenzocimab, placebo - Acute Ischemic Stroke | Phase 2 / Phase 3 | Withdrawn | Fondation Ophtalmologique Adolphe de Rothschild | 2026-09-01 | 2026-09-09 | |
| Terazosin And Metabolic Engagement in Parkinson's Disease Terazosin Hydrochloride, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Withdrawn | Nandakumar Narayanan | 2026-09-01 | 2026-10-07 | |
| Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC Ga-68- DOTATATE, Ga-68-DOTATOC - Meningioma | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2026-08-01 | 2026-08-31 | |
| Laryngeal Vibro-tactile Stimulation as a Non-invasive Symptomatic Treatment for Spasmodic Dysphonia vibro-tactile stimulation (VTS) - Adductor Spasmodic Dysphonia, Abductor Spastic Dysphonia | Phase 2 | Withdrawn | University of Minnesota | 2026-08-01 | 2025-05-16 | |
| Post-Operative Steroids After Sleep Surgery 8mg dexamethasone - Obstructive Sleep Apnea | Phase 2 | Withdrawn | Medical University of South Carolina | 2026-07-01 | 2026-10-06 | |
| SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose - Lung Cancer, Head and Neck Cancer | Phase 2 | Withdrawn | Sound Pharmaceuticals, Incorporated | 2026-06-01 | 2026-06-03 | |
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss SPI-1005 200mg, SPI-1005 400mg, Placebo - Noise Induced Hearing Loss | Phase 2 | Withdrawn | Sound Pharmaceuticals, Incorporated | 2026-06-01 | 2026-06-03 | |
| A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors Utidelone, Bevacizumab - Malignant Solid Tumor, Brain Metastasis | Phase 2 | Withdrawn | Tianjin Medical University Cancer Institute and Hospital | 2026-05-01 | 2026-07-16 | |
| Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis Amniotic fluid or placental CD117 stem cells - Multiple Sclerosis, Progressive | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2026-02-01 | 2026-02-06 | |
| Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia Bacillus Calmette Guerin Vaccine, Saline Injection - Fibromyalgia | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2024-11-21 | |
| Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke Minocyclin - Acute Ischemic Stroke | Phase 2 | Withdrawn | State University of New York at Buffalo | 2025-12-01 | 2026-03-06 |
Showing 20 of 418. Sign in to see all of them.
Brain Neoplasms (35) · Parkinson Disease (26) · Stroke (21) · Alzheimer Disease (20) · Ischemic Stroke (20) · Multiple Sclerosis (18) · Brain Injuries, Traumatic (17) · Glioblastoma (13) · Amyotrophic Lateral Sclerosis (11) · Central Nervous System Neoplasms (11) · Breast Neoplasms (9) · Central Nervous System Diseases (9) · Cognitive Dysfunction (9) · Neuralgia (9)
Central Nervous System Diseases (232) · Brain Diseases (210) · Pathological Conditions, Signs and Symptoms (148) · Neurologic Manifestations (109) · Signs and Symptoms (108) · Neurodegenerative Diseases (71) · Neoplasms (70) · Neuromuscular Diseases (66) · Neoplasms by Site (65) · Cardiovascular Diseases (61) · Nervous System Neoplasms (60) · Vascular Diseases (60) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (56) · Cerebrovascular Disorders (55)
Sodium Chloride (12) · Dexmedetomidine (9) · Temozolomide (8) · Saline Solution (6) · Cyclophosphamide (5) · Magnetic Resonance Spectroscopy (5) · Propofol (5) · nabiximols (5) · Acetaminophen (4) · Botulinum Toxins, Type A (4) · Carboplatin (4) · Dexamethasone (4) · Ketamine (4) · Methylprednisolone (4) · Midazolam (4)
Washington University School of Medicine (8) · Johns Hopkins University (6) · M.D. Anderson Cancer Center (6) · Massachusetts General Hospital (6) · Brigham and Women's Hospital (5) · Duke University (5) · Columbia University (4) · Mayo Clinic (4) · NYU Langone Health (4) · National Institute of Neurological Disorders and Stroke (NINDS) (4) · Novartis Pharmaceuticals (4) · Pfizer (4) · Stanford University (4) · University of Minnesota (4) · University of Utah (4)
United States (204) · Canada (15) · United Kingdom (10) · France (9) · Germany (9) · Australia (7) · Israel (7) · China (6) · Belgium (5) · Brazil (5) · India (5) · Italy (4) · Mexico (4) · Norway (4) · Spain (4)
Alfred E Slonim, MD (2) · Alok K Sharma, MS,MCh (2) · Baorong Zhang, MD (2) · John G. Nutt, MD (2) · Jonathan Kil, MD (2) · Jonathan L. Finlay, MB, ChB (2) · Michael Levy, MD, PhD (2) · Vinay K. Puduvalli, MD (2) · Adam H de Havenon, MD (1) · Adam M Zanation, MD (1)
PMID 12064356, PMID 12084892, PMID 12628059, PMID 15703014, PMID 15784740, PMID 16002461, PMID 16194720, PMID 16457083, PMID 16510383, PMID 16861095, PMID 16886975, PMID 16908728, PMID 18268187, PMID 18414145, PMID 19194764, PMID 19660971, PMID 19734516, PMID 19949909, PMID 20338795, PMID 20566609, PMID 20627413, PMID 20954243, PMID 21868066, PMID 21990811, PMID 22370242, PMID 22700728, PMID 23335971, PMID 23370086, PMID 24127913, PMID 24471697, PMID 25338927, PMID 26387127, PMID 26808752, PMID 26926875, PMID 27439031, PMID 28357821, PMID 28452678, PMID 28509693, PMID 29037377, PMID 29285576, PMID 30054011, PMID 30152015, PMID 30232735, PMID 30402285, PMID 30877613, PMID 31694924, PMID 32583883, PMID 33203645, PMID 33324899, PMID 33778150
2018 (4), 2023 (3), 2017 (2), 1UF1AG046143 (1), 2016 (1), 2019 (1), I21RX004417 (1), K08MH094441 (1), K23AT001933 (1), K23NS050485 (1), M01RR000334 (1), P30CA016058 (1), P30CA022453 (1), P30CA033572 (1), P30CA072720 (1)